Can Liver MRI Predict Aggressive Small Tumor Recurrence?

Can Liver MRI Predict Aggressive Small Tumor Recurrence?

Surgical resection offers a potentially curative option for patients with small liver tumors. However, aggressive histological variants such as macrotrabecular-massive HCC frequently cause early disease relapse. Consequently, clinicians need accurate preoperative imaging tools to identify high-risk biological features before hepatic resection. Moreover, a recent study shows that preoperative Gd-EOB-DTPA-enhanced MRI reliably identifies this subtype in tumors under 3 cm. Furthermore, specific imaging hallmarks accurately predict the risk of three-year postoperative tumor recurrence.

Key Imaging Signs of Macrotrabecular-Massive HCC

The macrotrabecular-massive variant represents a biologically aggressive subtype of hepatocellular carcinoma. Pathologists associate this phenotype with prominent vascular invasion and rapid recurrence. Therefore, noninvasive identification before surgery provides significant clinical utility. The multicenter investigation evaluated 315 consecutive patients with surgically confirmed small hepatocellular carcinoma. Specifically, the cohort included 226 patients in a training set and 89 patients in an independent validation set.

Multivariate analysis revealed three critical imaging predictors on Gd-EOB-DTPA-enhanced MRI. First, a hypovascular tumor component of 20% or greater strongly indicated aggressive histology. Second, the presence of an intratumoral artery signaled significant tumor neoangiogenesis. Third, an incomplete tumor capsule reliably distinguished aggressive lesions from conventional nodules. Together, these three independent markers formed a robust preoperative predictive model. In the validation cohort, the model achieved an area under the curve of 0.75, with 77.4% sensitivity and 72.4% specificity.

Predicting Postoperative Recurrence and Patient Outcomes

Preoperative risk stratification substantially impacts long-term survival following liver resection. Notably, patients harboring two or three imaging risk factors faced a significantly higher risk of disease relapse. The multivariable Cox proportional hazards analysis demonstrated a hazard ratio of 2.55 for three-year recurrence. Thus, tumor biology profoundly influences recurrence even in early-stage, small hepatocellular carcinomas.

Furthermore, Kaplan-Meier curves confirmed stark differences in recurrence-free survival between risk groups. Patients presenting with two or three imaging predictors experienced markedly shorter disease-free intervals. This significant divergence persisted across both the training cohort and the validation cohort. Consequently, preoperative MRI provides essential prognostic insights beyond simple anatomical tumor sizing. Hepatobiliary surgeons can leverage this data to anticipate relapse patterns and design targeted follow-up regimens.

Clinical Implications for Surgical and Oncology Practice

These findings offer immediate relevance for clinicians managing liver cancer in Indian tertiary care centers. Currently, surgeons often consider lesions under 3 cm as low-risk early disease. However, underlying tumor aggressiveness can silently undermine successful curative resection. Identifying high-risk features on gadoxetic acid-enhanced MRI enables clinicians to consider wider surgical margins. Additionally, teams might recommend anatomical liver resection over non-anatomical wedge resections in high-risk candidates.

Moreover, postoperative surveillance schedules require adaptation based on individual biological risk. High-risk patients likely benefit from accelerated surveillance protocols with frequent multiphasic imaging. Clinicians can also discuss early adjuvant systemic therapy or clinical trial enrolment for these vulnerable patients. Ultimately, routine evaluation of intratumoral arteries, hypovascular components, and capsular integrity transforms preoperative planning into truly personalized oncology care.

Frequently Asked Questions

Q1: What defines the macrotrabecular-massive subtype of hepatocellular carcinoma?

This distinct subtype features thick tumor trabeculae measuring six or more cells in width. Pathologically, it exhibits aggressive behavior, vascular invasion, and elevated recurrence rates.

Q2: Which preoperative MRI findings best predict this aggressive subtype in small tumors?

Three independent features on Gd-EOB-DTPA-enhanced MRI predict this subtype. These include a hypovascular component of at least 20%, an intratumoral artery, and an incomplete capsule.

Q3: How does the presence of these imaging markers impact recurrence-free survival?

Patients showing two or three imaging markers face a 2.55-fold higher risk of three-year recurrence. Consequently, these individuals require rigorous postoperative surveillance and risk-adapted treatment.

References

1. Yang L et al. Preoperative Gd-EOB-DTPA-enhanced MRI may help predict macrotrabecular-massive subtype and postoperative recurrence in small hepatocellular carcinoma (≤ 3 cm). Eur Radiol. 2026 Sep 14. doi: 10.1007/s00330-026-12872-2. PMID: 42734666.
2. Mulé S, Tenenhaus A, Dioguardi Burgio M, et al. Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology. 2020;295(3):562-571. doi: 10.1148/radiol.2020192230.
3. Rhee H, Cho ES, Nahm JH, et al. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications. J Hepatol. 2021;74(1):109-121. doi: 10.1016/j.jhep.2020.08.013.